Future oncology最新文献_第8页

Postoperative nomogram for predicting involved lymph node in differentiated thyroid carcinoma: an observational study. 分化型甲状腺癌术后形态图预测受累淋巴结：一项观察性研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-09 DOI: 10.1080/14796694.2025.2543233

Yunbo Li, Junyan Wang, Jinzi Hui, Guangdong Hou, Wei He, Tao Sun, Liuyan Gao, Yixin Wei, Wei Zhang, Long Zheng, Peng Yuan, Menghui Yuan

{"title":"Postoperative nomogram for predicting involved lymph node in differentiated thyroid carcinoma: an observational study.","authors":"Yunbo Li, Junyan Wang, Jinzi Hui, Guangdong Hou, Wei He, Tao Sun, Liuyan Gao, Yixin Wei, Wei Zhang, Long Zheng, Peng Yuan, Menghui Yuan","doi":"10.1080/14796694.2025.2543233","DOIUrl":"10.1080/14796694.2025.2543233","url":null,"abstract":"Objective: This study aims to develop a comprehensive nomogram to accurately predict differentiated thyroid cancer (DTC) involved lymph node, enabling the personalization of treatment plans and optimizing patient outcomes.Methods: The nomogram was developed through an analysis of data obtained from derivation cohorts. To identify independent predictors of involved lymph node, we utilized the Least Absolute Shrinkage and Selection Operator (LASSO) method in conjunction with multivariable logistic regression. These predictive factors were subsequently integrated into the nomogram's design. To ensure the tool's robustness and clinical applicability, we assessed its discriminative ability, calibration, and clinical utility in both the derivation cohort and an independent validation cohort.Results: The identification of four key parameters - Thyroglobulin, Lymphocyte count, BRAFV600E, and the number of tumor foci - emerged as robust predictors of involved lymph node. The nomogram demonstrated outstanding performance across calibration, discrimination, and clinical applicability, with predictive accuracies of 0.992 in the derivation cohort and 0.920 in the validation cohort.Conclusion: Peripheral lymphocyte counts have been found to correlate with involved lymph node in DTC patients. A nomogram tailored specifically for predicting involved lymph node in DTC guides personalized postoperative radioactive iodine (RAI) and plays a critical role in the preoperative assessment.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2785-2793"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01). 四模态膀胱保存与avelumab治疗肌肉侵袭性尿路上皮癌：一项II期试验（TRIUMPH-B01）

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-25 DOI: 10.1080/14796694.2025.2549244

Ali Shamseddine, Noura Abbas, Sally Temraz, Monita Al Darazi, Maya Charafeddine, Kristel Dagher, Bassem Youssef, Rami Nasr, Raja Khauli, Albert El Hajj, Muhammad Bulbul

{"title":"Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01).","authors":"Ali Shamseddine, Noura Abbas, Sally Temraz, Monita Al Darazi, Maya Charafeddine, Kristel Dagher, Bassem Youssef, Rami Nasr, Raja Khauli, Albert El Hajj, Muhammad Bulbul","doi":"10.1080/14796694.2025.2549244","DOIUrl":"https://doi.org/10.1080/14796694.2025.2549244","url":null,"abstract":"Background/aims: Muscle-invasive bladder cancer (MIBC) has a 5-year survival rate of 40-60% following traditional treatment with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), which significantly impacts quality of life. Bladder preservation strategies, including maximal transurethral resection of the bladder tumor (TURBT), NAC, and radiation therapy, offer similar survival rates with better quality of life. Immune checkpoint inhibitors like avelumab show potential benefits when combined with bladder preservation modalities. This phase II randomized, non-comparative, double-arm, open-label, multicenter trial evaluates the efficacy and safety of two tetra-modality bladder preservation strategies in MIBC patients (T2-T4N0M0). The primary endpoint is the 2-year proportion of bladder-preserved participants. Secondary endpoints include response rates post-induction, quality of life, and safety evaluations.Methods: Eighty participants will be randomized 1:1 into Arm A or Arm B. All participants will first receive induction chemotherapy (DDMVAC or GC) combined with avelumab, followed by disease evaluation using imaging and TURBT. Those achieving a complete or near-complete response will proceed to hypofractionated radiation therapy (55 Grays in 20 fractions). After radiation, Arm A will receive maintenance avelumab for 1 year, while Arm B will follow a watch-and-wait approach. Non-responders in both arms will be referred for salvage RC.Clinical trial registration: NCT06686381 (ClinicalTrials.gov).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":2.6,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals. 在英国获得指导治疗的生物标志物：癌症患者和医疗保健专业人员的调查。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-08-08 DOI: 10.1080/14796694.2025.2535098

Dany Bell, Rachel Bryce, Rosalia Delfino, Nadia Godin-Heymann, Jessica Horne, Louise Jäger, Michael Jones, Niklas Magnell, Vishali Sharma, David Shera, Marianne J Ratcliffe, Kathy Walls, Rosie Mughal

{"title":"Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals.","authors":"Dany Bell, Rachel Bryce, Rosalia Delfino, Nadia Godin-Heymann, Jessica Horne, Louise Jäger, Michael Jones, Niklas Magnell, Vishali Sharma, David Shera, Marianne J Ratcliffe, Kathy Walls, Rosie Mughal","doi":"10.1080/14796694.2025.2535098","DOIUrl":"10.1080/14796694.2025.2535098","url":null,"abstract":"Aims: To understand current barriers to treatment-guiding biomarker testing in cancer patients in the UK.Methods: A literature search, interviews with healthcare professionals, and a focus group of cancer patients were used to identify current challenges and barriers to treatment guiding biomarker testing. These were followed by online surveys of healthcare professionals and patients designed to further explore and quantify challenges to biomarker testing within the UK.Results: Challenges were identified across the entire biomarker testing pathway, the most common being insufficient workforce, long turnaround times, and lack of specific training. These challenges had a negative impact on patient access to targeted cancer therapies.Conclusions: Challenges to accessing treatment-guiding biomarker testing of cancer patients within the UK are impacting clinical decision-making. There is a requirement to improve awareness and training of healthcare professionals, particularly nurses and advanced clinical practitioners, with opportunities to improve outdated and fragmented ordering and reporting processes. Steps should also be taken to improve the availability of plain-language information materials for patients, to promote understanding and self-advocacy.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2625-2636"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient preferences for treatment pathways in early-stage breast cancer: application of a discrete choice experiment. 早期乳腺癌患者对治疗途径的偏好：离散选择实验的应用。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-06-16 DOI: 10.1080/14796694.2025.2517000

Christian Jackisch, Chikako Shimizu, Emuella Flood, Oliver Will, Susan McCutcheon, Stella Mokiou, Xavier Guillaume, Emily Mulvihill, Kathleen Beusterien

{"title":"Patient preferences for treatment pathways in early-stage breast cancer: application of a discrete choice experiment.","authors":"Christian Jackisch, Chikako Shimizu, Emuella Flood, Oliver Will, Susan McCutcheon, Stella Mokiou, Xavier Guillaume, Emily Mulvihill, Kathleen Beusterien","doi":"10.1080/14796694.2025.2517000","DOIUrl":"10.1080/14796694.2025.2517000","url":null,"abstract":"Aim: This study assessed patient preferences for four clinical trial pathways, which include multiple sequential treatments, in human epidermal growth factor receptor 2-negative early-stage breast cancer (eBC). It presents an innovative application for a discrete choice experiment (DCE), yielding single-preference weights for complex pathways.Materials & methods: Patients in Germany, Italy, and Japan with stage II/III BC completed an online DCE, which included a series of choice tasks with two hypothetical treatment profiles that varied in attributes associated with four eBC treatment pathways: overall pathway (event-free survival, fixed versus flexible, duration) and treatment-specific (side effects, regimen). Bayes modeling was used to estimate preference weights for each attribute level. Preferences for different eBC pathways were calculated by summing the respective pathway and treatment weights, adjusted for the duration of the respective treatments along the pathway. Mean pathway preference weights were compared among the four pathways and countries using analyses of variance.Results: Pathway preferences were highly sensitive to treatment toxicity and surgical response. Additionally, a flexible pathway was preferred as it can mean a shorter pathway duration.Conclusion: Discussions with patients should be personalized per individual preferences and should cover the entire treatment pathway, not just the initial treatment step.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2311-2319"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review. 腱鞘巨细胞瘤的经济和人文负担：一项有针对性的文献综述。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-06-22 DOI: 10.1080/14796694.2025.2520744

Michiel van de Sande, Jean-Yves Blay, William Tap, Max Lee, Emily Kaiser, Steph Beaver, Brooke Harrow, Nicholas A Zeringo, Nicholas Bernthal

{"title":"The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review.","authors":"Michiel van de Sande, Jean-Yves Blay, William Tap, Max Lee, Emily Kaiser, Steph Beaver, Brooke Harrow, Nicholas A Zeringo, Nicholas Bernthal","doi":"10.1080/14796694.2025.2520744","DOIUrl":"10.1080/14796694.2025.2520744","url":null,"abstract":"Aim: To understand the epidemiology, treatment patterns, economic burden, and humanistic burden of tenosynovial giant cell tumor (TGCT) in the contemporary treatment landscape.Methods: Embase, MEDLINE, and select conferences were searched to identify studies published between 1 January 2013, and 22/23 August 2023 (database dependent) that included ≥ 20 TGCT patients (≥ 40 for humanistic burden studies). For economic outcomes and treatment patterns, data from 1 January 2008, and later were included.Results: A total of 35 studies were included. The incidence of TGCT was < 50 cases/million person-years. Surgery was the most common treatment, for which recurrence rates were up to 67%. While quality of life improved after surgery in the absence of recurrence, repeat surgeries for persistent symptoms or recurrent tumors negatively impacted quality of life and inflicted a high economic burden. Systemic therapies were effective and overall improved patient symptoms and quality of life. Treatment was multidisciplinary and involved orthopedic surgeons and medical oncologists as well as supplemental care such as physical therapy.Conclusion: TGCT has a high burden, which can be exacerbated by repeat surgeries. Systemic therapies may improve disease and quality of life outcomes in some patients with tumors that are locally advanced or in complicated anatomical locations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2385-2400"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12323415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative durvalumab for muscle invasive bladder cancer: the start of a new chapter. 肌肉浸润性膀胱癌的围手术期杜伐单抗：新篇章的开始。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-16 DOI: 10.1080/14796694.2025.2531574

Elizabeth Nally, Thomas Powles

引用次数: 0

Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study. egfr突变的非小细胞肺癌的分子检测、治疗模式和结果：双鱼座研究

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-28 DOI: 10.1080/14796694.2025.2529094

Panwen Tian, Lin Wu, Chengzhi Zhou, Jie Tan, Ke Wang, Feng Luo, Yongmei Liu, Yubiao Guo, Yinyin Li, Zhe Liu, Youling Gong, Yongsheng Wang, Jinghong Xian, Weimin Li

{"title":"Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study.","authors":"Panwen Tian, Lin Wu, Chengzhi Zhou, Jie Tan, Ke Wang, Feng Luo, Yongmei Liu, Yubiao Guo, Yinyin Li, Zhe Liu, Youling Gong, Yongsheng Wang, Jinghong Xian, Weimin Li","doi":"10.1080/14796694.2025.2529094","DOIUrl":"10.1080/14796694.2025.2529094","url":null,"abstract":"Background: This study investigated molecular testing, treatment patterns, and prognosis in Chinese patients who progressed from first-line (1 L), epidermal growth factor receptor -tyrosine kinase inhibitors (EGFR-TKIs) therapy, highlighting limited real-world data on clinical practice.Methods: Consecutive eligible patients were prospectively enrolled in 16-centers in China. The primary endpoints were second-line (2 L) treatment patterns and clinical outcomes, including median progression-free survival (mPFS) and median overall survival (mOS) from 2 L treatment.Results: Overall, 300 patients were enrolled in the study, and among them, 291 patients were included in the Full Analysis Set, and 213(73.2%) underwent molecular testing, after progression from 1 L therapy. 30.5% (65/213) had tissue samples, while 66.7% (142/213) had plasma samples. In tissue and plasma samples, T790M positive rates were 53.8% and 43.7%, respectively. mPFS and mOS for patients with T790M positive who received third generation (3 G) EGFR-TKIs as 2 L therapy were 14.7 months and 32.0 months, respectively. The mPFS for patients with T790M negative who received 3 G EGFR-TKIs, prior EGFR-TKIs plus local therapy, and chemotherapy as 2 L therapy were 7.6 months, 10.2 months, and 4.9 months, respectively. The corresponding mOS for these patients were 21.2 months, 16.6 months, and 15.0 months, respectively. No new safety signal emerged.Conclusions: Patients with acquired resistance to first generation (1 G)/second generation (2 G) EGFR-TKIs receiving 3 G EGFR-TKIs, especially T790M positive, showed better clinical outcomes after molecular testing.Clinical trial registration: The study has been registered at ClinicalTrials.gov (NCT04207775).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2537-2547"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detecting metabolic signatures in endometrial cancer: potential applications of Raman spectroscopy. 检测子宫内膜癌的代谢特征：拉曼光谱的潜在应用。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-12 DOI: 10.1080/14796694.2025.2530920

Tze Hua Yeu, Intan Sofia Omar, Soke Chee Kwong, Nur Akmarina B M Said, S F Abdul Sani, Amira Hajirah Abd Jamil, Ivy Chung

{"title":"Detecting metabolic signatures in endometrial cancer: potential applications of Raman spectroscopy.","authors":"Tze Hua Yeu, Intan Sofia Omar, Soke Chee Kwong, Nur Akmarina B M Said, S F Abdul Sani, Amira Hajirah Abd Jamil, Ivy Chung","doi":"10.1080/14796694.2025.2530920","DOIUrl":"10.1080/14796694.2025.2530920","url":null,"abstract":"Endometrial cancer (EC) is intricately linked to obesity, with metabolic reprogramming increasingly established to drive oncogenic transformation and influence treatment outcomes. Implementation of early detection strategy significantly reduces morbidity and mortality; however, screening strategies lack the required sensitivity, specificity, and accuracy to be successfully implemented in clinical practice. Current diagnostic approaches are also invasive, costly, and time-consuming, highlighting a gap in developing diagnostic and screening alternatives for EC among high-risk individuals, especially with sensitivity to capture cancer-specific changes. Raman Spectroscopy is an emerging tool in medical diagnostics. By exploiting the atomic vibrational absorption induced by the interaction of light with a biological sample, a unique spectral response namely a \"metabolite fingerprint\" can be generated. This nondestructive technique combined with multivariate statistical analysis can characterize metabolic discrimination between cancerous and healthy samples, demonstrating a promising role in cancer screening, diagnosis, and monitoring of treatment outcomes. This review aimed to collate available evidence on Raman's ability to capture metabolic abnormalities, particularly cancer-specific metabolites during malignant transformation and therapeutic resistance. Given that cellular metabolism is altered in EC, this review will provide insight into its potential applications for EC screening, diagnosis, and prospects, especially for monitoring treatment outcomes among high-risk patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2663-2687"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144617234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A real-world evaluation of the rapid diagnostic clinic roll out in South East London. 快速诊断诊所在伦敦东南部推出的真实世界的评估。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-23 DOI: 10.1080/14796694.2025.2525016

Beth Russell, Maria J Monroy-Iglesias, Charlotte Louise Moss, Mieke Van Hemelrijck, Sarah Weild, Elisabetta Fabris, Saoirse Dolly, Geraint Jones, Kate Haire

{"title":"A real-world evaluation of the rapid diagnostic clinic roll out in South East London.","authors":"Beth Russell, Maria J Monroy-Iglesias, Charlotte Louise Moss, Mieke Van Hemelrijck, Sarah Weild, Elisabetta Fabris, Saoirse Dolly, Geraint Jones, Kate Haire","doi":"10.1080/14796694.2025.2525016","DOIUrl":"10.1080/14796694.2025.2525016","url":null,"abstract":"Introduction: Rapid Diagnostic Clinics (RDCs) are an established urgent suspected cancer pathway in England and Wales for patients presenting with non-site-specific (NSS) but concerning symptoms for cancer.Methods: This evaluation included data from a six-month period from 1 September 2022 to 28 February 2023. Information on all patients seen at the three South East London (SEL) RDCs within this six month period was extracted from the REDCap database. Data were analyzed according to several evaluation domains: efficiency, effectiveness (including information on patient demographics, number of referrals, referral outcomes) and patient and GP experience.Results: Eight hundred and sixty-two patients were seen by the SEL RDCs. Most patients came from referrals from general practitioners (GPs) (93%). Only 24 patients (4.5%) were re-referred to the RDC or another specialty within 90 days of discharge and none of these patients were subsequently diagnosed with cancer. There were 47 subsequent cancer diagnoses (6%). The proportion of serious benign conditions diagnosed ranged from 15% to 19% per month. Patient and GP experiences were very positive about the service.Conclusions: This evaluation has demonstrated that the SEL RDC services provide an effective pathway for the management of patients with concerning non-site-specific symptoms with the ability to diagnose both cancer and non-cancer conditions.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2451-2458"},"PeriodicalIF":2.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selpercatinib in the treatment of thyroid cancer. Selpercatinib在甲状腺癌治疗中的应用。

IF 2.6 4区医学

Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-10 DOI: 10.1080/14796694.2025.2531575

Thibault Gauduchon, Romain Varnier, Philippe A Cassier

引用次数: 0